Arctic Bioscience – Mandatory notification of trade

Siglar AS, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today bought 20,000 shares in Arctic Bioscience at an average price of NOK 2,32 per share. Following the transaction, Siglar AS holds 20,000 shares in Arctic Bioscience. In addition, Siglar AS holds 50% ownership of Capra Invest AS, which holds 1,544,450 in Arctic Bioscience.

Chairman of the Board at Arctic Bioscience, Harald Nordal, is the owner of Siglar AS.

Please refer to the attached notification of trading for further details. 

This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act § 5-12.

For more information, please contact:

Jone R. Slinning

CFO

Phone: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.

The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.